Genetic susceptibility to acute viral bronchiolitis

Approved

Classifications

MinEdu publication type
A1 Journal article (peer-reviewed)
Definition
Article
Target group
Scientific
Peer reviewed
Peer-reviewed
Article type
Journal article
Host publication type
Journal

Authors of the publication

Number of authors
6
Authors
Pasanen, Anu; Karjalainen, Minna K; Korppi, Matti; Hallman, Mikko; Rämet, Mika; for the Research Project FinnGen

Publication channel information

Title of journal/series
Journal of infectious diseases
ISSN (print)
0022-1899
ISSN (electronic)
1537-6613
ISSN (linking)
0022-1899
Publisher
Oxford University Press
Publication forum ID
60673
Publication forum level
2
Country of publication
United States
Internationality
Yes

Detailed publication information

Publication year
2024
Reporting year
2024
Journal/series volume number
[Epub ahead of print 20 Sep 2024]
Article number
jiae467
DOI
10.1093/infdis/jiae467
Language of publication
English

Co-publication information

International co-publication
No
Co-publication with a company
No

Availability

Link to online publication
Link to self-archived version

Classification and additional information

MinEdu field of science classification
3123 Gynaecology and paediatrics, 3121 General medicine, internal medicine and other clinical medicine
Keywords
CDHR3; GSDMB; ORMDL3; acute lower respiratory infection; asthma; bronchiolitis; genetic risk factors; non-RSV bronchiolitis; respiratory syncytial virus; rhinovirus

Funding information

Funding information in the publication
This work was supported by Stiftelsen Alma och K.A. Snellman Foundation (AP), Sigrid Jusélius Foundation (MH), and Foundation for Pediatric Research (MR). FinnGen funding statement: The FinnGen project is funded by two grants from Business Finland (HUS 4685/31/2016 and UH 4386/31/2016) and the following industry partners: AbbVie Inc., AstraZeneca UK Ltd, Biogen MA Inc., Bristol Myers Squibb (and Celgene Corporation & Celgene International II Sàrl), Genentech Inc., Merck Sharp & Dohme LCC, Pfizer Inc., GlaxoSmithKline Intellectual Property Development Ltd., Sanofi US Services Inc., Maze Therapeutics Inc., Janssen Biotech Inc, Novartis AG, and Boehringer Ingelheim International GmbH.

Research data information

Research data information in the publication
The GWAS summary data will be made available in the NHGRI-EBI Catalog of human genome-wide association studies upon publication.

Source database ID

WoS ID
WOS:001424716700001
Other database ID
PMID: 39299705